Chromosomal abnormalities, p53 and Bcl-2 expression and clinical outcome in choroidal melanoma

Melanoma Research

Volumn 14, Issue 6, 2004, Pages 473-478

  Erol, Nazmiye ^a   Öner, Ülkü ^a   Artan, Sevilhan ^a   Işiksoy, Serap ^a   Yurdakul, Sumru ^a  

^a OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

Author keywords

Bcl 2; Comparative genomic hybridization; p53; Uveal malignant melanoma

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SURVIVAL; CASE REPORT; CAUSE OF DEATH; CELL TYPE; CHOROID MELANOMA; CHROMOSOME 17P; CHROMOSOME 18Q; CHROMOSOME 3; CHROMOSOME 6Q; CHROMOSOME 7Q; CHROMOSOME 8; CHROMOSOME ABERRATION; CHROMOSOME DELETION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SPINDLE CELL;

ADULT; AGED; CHOROID NEOPLASMS; CHROMOSOME ABERRATIONS; EPITHELIOID CELLS; FEMALE; GENE DOSAGE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPING; MALE; MELANOMA; MIDDLE AGED; NEVUS, SPINDLE CELL; NUCLEIC ACID HYBRIDIZATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 13544258023     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200412000-00006     Document Type: Article

References (33)

1. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. Lancet 1996; 347:1222-1225.
2. Horsman DE, White VA. Cytogenetic analysis of uveal melanoma. Consistent occurrence of monosomy 3 and trisomy 8q. Cancer 1993; 71:811-819.
3. White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE. Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 1998; 83:354-359.
4. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. Wild type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 1992; 70:937-948.
5. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild type p53. Cell 1992; 70:923-935.
6. Diller L, Kassel J, Nelson CE, Gryka MA, Litwak G, Gebhardt M, et al. p53 functions as a cell cycle control protein in osteosarcomas. Mol Cell Biol 1990; 10(11):5772-5781.
7. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 51(23 Pt 1):6304-6311.
8. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991; 164:75-81.
9. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Lukas J, Rejthar A, et al. Aberrant expression of p53 protein is a common feature of a wide spectrum of human malignancies. Oncogene 1991; 6:1699-1703.
10. Jiang W, Ananthaswamy HN, Muller HK, Kripke ML. p53 protects against skin cancer induction by UV-B radiation. Oncogene 1999; 18(29): 4247-4253.
11. Bolshakov S, Walker CM, Strom SS, Selvan MS, Clayman GL, El-Naggar A, et al. p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas. Clin Cancer Res 2003; 9(1):228-234.
12. Seddon JM, Gragoudas ES, Glynn RJ, Egan KM, Albert DM, Blitzer PH. Host factors, UV irradiation, and risk of uveal melanoma: a case-control study. Arch Ophthalmol 1990; 108:1274-1280.
13. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of Bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994; 9:1799-1805.
14. Morales-Ducret CRJ, Van De Rijn M, Smoller BR. Bcl-2 expression in melanocytic nevi. Insights into the biology of dermal maturation. Arch Dermatol 1995; 131:915-918.
15. Hockenbery DM, Zutter M, Hickey W, Nahm M, Korsmeyer SJ. BCL2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991; 88(16):6961-6965.
16. Arslantaş A, Artan S, Öner Ü, Durmaz R, Müslümanoǧlu H, Atasoy MA, et al. Detection of chromosomal imbalances in spinal meningiomas by comparative genomic hybridization. Neurol Med Chir 2003; 43:12-19.
17. Tobal K, Warren W, Cooper CS, McCartney A, Hungerfold J, Lightman S. Increased expression and mutation of p53 in choroidal melanoma. Br J Cancer 1992; 66:900-904.
18. Chana JS, Wilson GD, Cree IA, Alexander RA, Myatt N, Neale M, et al. C-myc, p53 and Bcl-2 expression and clinical outcome in uveal melanoma. Br J Ophthalmol 1999; 83:110-114.
19. Kishore K, Ghazvini S, Char DH, Kroll S, Selle J. p53 gene and cell cycling in uveal melanoma. Am J Ophthalmol 1996; 121:561-567.
20. Brantley Jr MA, Harbour JW. Deregulation of the Rb and pathways in uveal melanoma. Am J Pathol 2000; 157:1795-1801.
21. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 8(2): 531-539.
22. Lehman TA, Bennett WP, Metcalf RA, Welsh JA, Ecker J, Modali RV, et al. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines. Cancer Res 1991; 51(15):4090-4096.
23. Iggo R, Gatter K, Bartek J, Lane D, Harris AL. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335:675-679.
24. Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84: 845-855.
25. Cristofolini M, Boi S, Girlando S, Zumiani G, Cristofollini P, Palma PD, et al. p53 expression in nevi and melanomas. Arch Dermatol 1993; 129:739-743.
26. Van den Oord JJ, Vandeghinste N, De Ley M, DeWolf-Peeters C. Bcl-2 expression in human melanocytes and melanocytic tumors. Am J Pathol 1994; 145:294-300.
27. Tschentscher F, Prescher G, Zeschnigk M, Horsthemke B, Lohmann DR. Identification of chromosomes 3, 6 and 8 aberrations in uveal melanoma by microsatellite analysis in comparison to comparative genomic hybridization. Cancer Genet Cytogenet 2000; 112:13-17.
28. White VA, McNeil BK, Horsman DE. Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma. Cancer Genet Cytogenet 1998; 102:40-45.
29. Scholes AGM, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. Invest Ophthalmol Vis Sci 2003; 44:1008-1011.
30. Patel KA, Edmondson ND, Talbot F, Parsons MA, Rennie IG, Sisley K. Prediction of prognosis in patients with uveal melanoma using fluorescence in situ hybridization. Br J Ophthalmol 2001; 85:1440-1444.
31. Aalto Y, Eriksson L, Seregard S, Larsson O, Knuutila S. Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. Invest Ophthalmol Vis Sci 2001; 42:313-317.
32. Knuutila S, Aalto Y, Autio K, Bjorkqvist AM, El-Rifai W, Hemmer S, et al. DNA copy number losses in human neoplasms. Am J Pathol 1999; 155: 683-694.
33. Coleman K, Baak JPA, Diest PV, Mullaney J, Farrell M, Fenton M. Prognostic factors following enucleation of 111 uveal melanomas. Br J Ophthalmol 1993; 77:688-692.